$1.26
8.03% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US28658R1068
Symbol
CLYM
Sector
Industry

Eliem Therapeutics Inc Stock price

$1.26
+0.02 1.61% 1M
-1.84 59.35% 6M
-0.54 30.00% YTD
-7.03 84.80% 1Y
-14.64 92.08% 5Y
-14.64 92.08% 10Y
-14.64 92.08% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.11 8.03%
ISIN
US28658R1068
Symbol
CLYM
Sector
Industry

Key metrics

Market capitalization $85.15m
Enterprise Value $-12.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.44
P/B ratio (TTM) P/B ratio 0.44
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-102.03m
Free Cash Flow (TTM) Free Cash Flow $-29.18m
Cash position $98.06m
EPS (TTM) EPS $-1.37
P/E forward negative
Short interest 6.44%
Show more

Is Eliem Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Eliem Therapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Eliem Therapeutics Inc forecast:

Buy
100%

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
138% 138%
-
- Research and Development Expense 28 28
217% 217%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -102 -102
414% 414%
-
Net Profit -93 -93
540% 540%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eliem Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eliem Therapeutics Inc Stock News

Neutral
GlobeNewsWire
24 days ago
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into em...
Neutral
GlobeNewsWire
29 days ago
Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial P...
Neutral
GlobeNewsWire
2 months ago
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office United States
CEO Aoife Brennan
Founded 2018
Website climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today